Cormedix Inc. (CRMD)
NASDAQ:CRMD
Want to see CRMD full AI Analyst Report?
CRMD Stock Chart & Stats
$7.39
$0.06(0.58%)
At close: 4:00 PM EST
$7.39
$0.06(0.58%)
Day’s Range― - ―
52-Week Range$6.13 - $17.43
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.24M
Market Cap
$631.35M
Enterprise Value$634.55M
Total Cash (Recent Filing)$149.52M
Total Debt (Recent Filing)$148.91M
Price to Earnings (P/E)16.4
Beta1.52
Next Earnings
May 14, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.21
Shares Outstanding78,428,090
10 Day Avg. Volume924,903
30 Day Avg. Volume1,242,809
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.07
Price to Sales (P/S)2.69
P/FCF Ratio4.85
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue2.04
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda3.84
Forecast
1Y Price Target
$13.75Price Target Upside86.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.66
Revenue Forecast (FY)$308.60M
Bulls Say, Bears Say
Bulls Say
Capital Structure And BuybacksA well-capitalized balance sheet combined with a share repurchase authorization provides financial flexibility to support the business and absorb near-term volatility while awaiting clinical results.
Clinical Trial ReadoutsLate-stage trial readout for Rezzayo as an antifungal prophylactic could act as a major catalyst by validating efficacy and unlocking multiple commercial use cases.
Pipeline Valuation And Market OpportunityRezzayo's favorable dosing profile and planned label expansions for Rezzayo and DefenCath point to a sizable addressable market that appears underpriced, offering upside if adoption occurs.
Bears Say
Earnings And Expense PressureReported GAAP expenses exceeded expectations and a tax-line adjustment distorted earnings comparisons, contributing to negative sentiment around profitability.
Reimbursement RiskA change in TDAPA reimbursement is expected to materially reduce DefenCath sales during a transition, creating a significant near-term revenue headwind.
Revenue Guidance ShortfallCompany revenue guidance came in below expectations, which reset investor expectations and exerted downward pressure on the stock.
Cormedix News
CRMD FAQ
What was Cormedix Inc.’s price range in the past 12 months?
Cormedix Inc. lowest stock price was $6.13 and its highest was $17.43 in the past 12 months.
What is Cormedix Inc.’s market cap?
Cormedix Inc.’s market cap is $631.35M.
When is Cormedix Inc.’s upcoming earnings report date?
Cormedix Inc.’s upcoming earnings report date is May 14, 2026 which is in 7 days.
How were Cormedix Inc.’s earnings last quarter?
Cormedix Inc. released its earnings results on Mar 05, 2026. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.816 by -$0.656.
Is Cormedix Inc. overvalued?
According to Wall Street analysts Cormedix Inc.’s price is currently Undervalued.
Does Cormedix Inc. pay dividends?
Cormedix Inc. does not currently pay dividends.
What is Cormedix Inc.’s EPS estimate?
Cormedix Inc.’s EPS estimate is 0.34.
How many shares outstanding does Cormedix Inc. have?
Cormedix Inc. has 78,428,090 shares outstanding.
What happened to Cormedix Inc.’s price movement after its last earnings report?
Cormedix Inc. reported an EPS of $0.16 in its last earnings report, missing expectations of $0.816. Following the earnings report the stock price went down -11.517%.
Which hedge fund is a major shareholder of Cormedix Inc.?
Currently, no hedge funds are holding shares in CRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cormedix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.75 (86.06% Upside)
$13.75 (86.06% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.65%
12-Months-Change
Fundamentals
Return on Equity
58.50%
Trailing 12-Months
Asset Growth
638.46%
Trailing 12-Months
Company Description
Cormedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CRMD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced several strong operational and financial achievements — including the Melinta acquisition, realization of $35M synergies, robust pro forma revenue ($401.3M), healthy cash (~$148.5M) and a clear pipeline catalyst with RIZEAO top-line data expected in Q2 2026 — against meaningful near-term headwinds tied to the TDAPA-to-bundle reimbursement transition, expected price erosion for DEFENCATH, customer concentration risk, and materially higher operating expenses following the merger. Management offered conservative guidance that reflects those reimbursement risks while preserving upside potential from Medicare Advantage contracting, inpatient adoption, and RIZEAO/TPN development programs. On balance, the positives around completed integration, liquidity, and upcoming clinical catalysts are offset by significant reimbursement and concentration risks that could materially pressure DEFENCATH revenue absent favorable contracting or legislative outcomes.View all CRMD earnings summariesCRMD Stock 12 Month Forecast
Average Price Target
$13.75
▲(86.06% Upside)
Technical Analysis
Arbutus Biopharma
―
Immatics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Zenas BioPharma, Inc.
―
Ownership Overview
2.91% Insiders
9.08% Mutual Funds
1.47% Other Institutional Investors
73.36% Public Companies and Individual Investors